Daratumumab, lenalidomide, and dexamethasone in East Asian patients with relapsed or refractory multiple myeloma: subgroup analyses of the phase 3 POLLUX study-Reference-Cited by-同舟云学术

Daratumumab, lenalidomide, and dexamethasone in East Asian patients with relapsed or refractory multiple myeloma: subgroup analyses of the phase 3 POLLUX study

Published:2018-04 Issue:4 Volume:8 Page:
ISSN:2044-5385
Container-title:Blood Cancer Journal
language:en
Short-container-title:Blood Cancer Journal

Author:

Suzuki Kenshi,Dimopoulos Meletios A.,Takezako Naoki,Okamoto Shinichiro,Shinagawa Atsushi,Matsumoto Morio,Kosugi Hiroshi,Yoon Sung-Soo,Huang Shang-Yi,Qin Xiang,Qi Ming,Iida Shinsuke

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Hematology

Link

http://www.nature.com/articles/s41408-018-0071-x.pdf

Reference22 articles.

1. de Weers, M. et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J. Immunol. 186, 1840–1848 (2011).

2. Lammerts van Bueren, J., et al. Direct in vitro comparison of daratumumab with surrogate analogs of CD38 antibodies MOR03087, SAR650984 and Ab79. Blood 124, Abstract 3474 (2014).

3. Overdijk, M. B. et al. Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma. mAbs 7, 311–321 (2015).

4. van de Donk, N. W. C. J. et al. Monoclonal antibodies targeting CD38 in hematological malignancies and beyond. Immunol. Rev. 270, 95–112 (2016).

5. Krejcik, J. et al. Daratumumab depletes CD38+ immune-regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma. Blood 128, 384–394 (2016).

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Epstein–Barr Virus Driven Hodgkin’s Lymphoma after a Short Course of Daratumumab Treatment for Relapsed Multiple Myeloma;Case Reports in Hematology;2023-12-18

2. Clinical Pharmacokinetics and Pharmacodynamics of Daratumumab;Clinical Pharmacokinetics;2023-05-02

3. Daratumumab plus bortezomib, cyclophosphamide, and dexamethasone in Asian patients with newly diagnosed AL amyloidosis: subgroup analysis of ANDROMEDA;Annals of Hematology;2023-03-02

4. Development of Epstein–Barr virus-associated lymphoproliferative disorder and hemophagocytic lymphohistiocytosis during long-term lenalidomide maintenance therapy in multiple myeloma;International Journal of Hematology;2022-12-13

5. Practice patterns and outcomes for triple-class exposed patients with relapsed/refractory multiple myeloma in Japan;Future Oncology;2022-11